ReviewInternational journal of molecular sciences2026

Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes.

Zuzanna Ratka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.